【省医保局】陕西“双目录”落地新增114种医保药 首设19种商保药

Core Insights - The implementation of the new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory (2025) and the Commercial Health Insurance Innovative Drug Directory (2025) has been launched in Shaanxi, adding 114 new drugs to the insurance coverage [1][2] - The new directory includes 50 innovative Class A drugs, focusing on areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [1] - The commercial insurance directory includes 19 innovative drugs that complement the basic medical insurance, addressing diverse medication needs of the public [1] Summary by Sections New Drug Additions - A total of 114 new drugs have been added to the insurance coverage, with 111 of them being newly launched in the past five years, marking a record high in both quantity and proportion [1] - The new drugs are characterized by higher cost-effectiveness, filling clinical gaps, and demonstrating superior efficacy compared to existing alternatives [1] Policy Implementation - The provincial medical insurance bureau has mandated that designated medical institutions hold special pharmaceutical meetings by the end of February 2026 to prioritize the allocation of negotiated drugs without restrictions from total expenditure control or drug proportion limits [2] - The management scope of special drugs has been adjusted, increasing the total to 337 drugs, with 59 new additions and 6 removals [2] Commercial Health Insurance Innovations - The newly established commercial health insurance innovative drug directory is designed to include 19 high-value innovative drugs that are not covered by basic medical insurance, promoting a multi-tiered healthcare security system [2] - This initiative aims to enhance the supply of healthcare coverage and facilitate the complementary development of commercial insurance alongside basic medical insurance [2]